drugset
drugset / Trial / NCT02500732

Prevention of Syncope Trial 6 - Atomoxetine in Vasovagal Syncope

NCT02500732 ↗

Phase 2 Completed 57 enrolled University of Calgary Cardiac Arrhythmia Network of Canada · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Objective: To determine if atomoxetine 40 mg bid (bis in die) in patients ≥18 years old with recurrent vasovagal syncope will better prevent syncope during tilt testing than placebo.

Timeline

Start
2015-07
Primary completion
2018-01
Completion
2018-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atomoxetine Other / unclassified 40 mg Oral

Indications

syncope, familial vasovagal